A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.

BioRxiv : the Preprint Server for Biology
Antonio E MuruatoPei-Yong Shi

Abstract

Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. Our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.

Citations

Sep 29, 2020·Emerging Microbes & Infections·Coleman BakerPei-Yong Shi
Oct 22, 2020·PeerJ·Ahmed E Dhamad, Muna A Abdal Rhida
Apr 13, 2021·Expert Review of Molecular Diagnostics·Jianfu J WangJin V Wu

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
antibody assay
Assay

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.